Matthew Zimmerman

3.9k total citations
57 papers, 2.4k citations indexed

About

Matthew Zimmerman is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Matthew Zimmerman has authored 57 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Infectious Diseases, 26 papers in Epidemiology and 22 papers in Molecular Biology. Recurrent topics in Matthew Zimmerman's work include Tuberculosis Research and Epidemiology (45 papers), Mycobacterium research and diagnosis (19 papers) and Cancer therapeutics and mechanisms (13 papers). Matthew Zimmerman is often cited by papers focused on Tuberculosis Research and Epidemiology (45 papers), Mycobacterium research and diagnosis (19 papers) and Cancer therapeutics and mechanisms (13 papers). Matthew Zimmerman collaborates with scholars based in United States, South Africa and Singapore. Matthew Zimmerman's co-authors include Véronique Dartois, Brendan Prideaux, Chao Chen, Laura E. Via, Firat Kaya, Clifton E. Barry, Martin Gengenbacher, Scott Wadler, Edward L. Schwartz and P H Wiernik and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Nature Medicine.

In The Last Decade

Matthew Zimmerman

53 papers receiving 2.4k citations

Peers

Countries citing papers authored by Matthew Zimmerman

Since Specialization

Citations

This map shows the geographic impact of Matthew Zimmerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Zimmerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Zimmerman more than expected).

Fields of papers citing papers by Matthew Zimmerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Zimmerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Zimmerman. The network helps show where Matthew Zimmerman may publish in the future.

Co-authorship network of co-authors of Matthew Zimmerman

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Zimmerman. A scholar is included among the top collaborators of Matthew Zimmerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Zimmerman. Matthew Zimmerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance 2025 ·The Journal of Infectious Diseases ·Annamarie E. Bustion, (unknown), Firat Kaya, (unknown), Jansy P. Sarathy, Landry Blanc, Marjorie Z. Imperial, Martin Gengenbacher, Min Xie, Matthew Zimmerman, Gregory T. Robertson, Dominique J. Wiener, Laura E. Via, Clifton E. Barry, Radojka M. Savić, Véronique Dartois	0
2	Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly 2025 ·Chemical Science ·(unknown), (unknown), Matthew Zimmerman, Curtis A. Engelhart, (unknown), Patrick K. Quoika, Andreas M. Kany, (unknown), (unknown), Joshua B. Wallach, Anna K. H. Hirsch, (unknown), Dirk Schnappinger, Véronique Dartois, Stephan A. Sieber	0
3	ACOD1-mediated lysosomal membrane permeabilization contributes to Mycobacterium tuberculosis –induced macrophage death 2025 ·Proceedings of the National Academy of Sciences ·Ziwei Yang, Li Zhang, (unknown), Jacob B. Geri, Andrew J. Perkowski, Xiuju Jiang, (unknown), Ruslana Bryk, Jeffrey Aubé, Matthew Zimmerman, Véronique Dartois, Carl Nathan	2
4	Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease 2025 ·ACS Infectious Diseases ·Jickky Palmae Sarathy, Min Xie, (unknown), Dereje A. Negatu, Sergio D. Rodríguez, Matthew Zimmerman, (unknown), (unknown), Mercedes Gonzalez‐Juarrero, Véronique Dartois, Thomas Dick	1
5	Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen 2024 ·Nature Communications ·Natasha Strydom, (unknown), Marjorie Z. Imperial, (unknown), Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, (unknown), Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P. Sarathy, Tian J. Yang, Véronique Dartois, Eric L. Nuermberger, Radojka M. Savić	7
6	Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis 2024 ·PLoS Pathogens ·(unknown), Ariel A. Aptekmann, Mikhail V. Keniya, (unknown), (unknown), (unknown), (unknown), Firat Kaya, Matthew Zimmerman, Diego H. Cáceres, Nancy A. Chow, David S. Perlin, Erika Shor	3
7	Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria 2022 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Matthew Zimmerman, (unknown), Michaele Josten, (unknown), (unknown), Hans Georg Sahl, Pedro M. Pereira, Mariana G. Pinho, Véronique Dartois, Ambrose L. Cheung, Courtney C. Aldrich	9
8	Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance 2022 ·Angewandte Chemie International Edition ·Tian Lan, Uday S. Ganapathy, Sachin Sharma, (unknown), Matthew Zimmerman, Vadim Molodtsov, (unknown), Martin Gengenbacher, Richard H. Ebright, Véronique Dartois, Joel S. Freundlich, Thomas Dick, Courtney C. Aldrich	15
9	CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis 2022 ·Nature Microbiology ·Shuqi Li, Nicholas C. Poulton, (unknown), (unknown), Michael A. DeJesus, Nadine Ruecker, Matthew Zimmerman, (unknown), Barbara Bosch, Curtis A. Engelhart, (unknown), Martin Gengenbacher, Véronique Dartois, Dirk Schnappinger, Jeremy M. Rock	96
10	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits 2021 ·Antimicrobial Agents and Chemotherapy ·Oluwaseun Francis Egbelowo, Jansy P. Sarathy, (unknown), Matthew Zimmerman, Han Wang, (unknown), Firat Kaya, Martin Gengenbacher, (unknown), (unknown), Carol A. Nacy, Bree B. Aldridge, Claire L. Carter, Paolo Denti, Véronique Dartois	17
11	Targeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs 2021 ·PLoS Biology ·(unknown), Calvin M. Johnson, (unknown), (unknown), (unknown), Jimmy S. Patel, (unknown), Riccardo Russo, (unknown), (unknown), (unknown), Matthew Zimmerman, J. Fraser Glickman, Joel S. Freundlich, Shumin Tan	13
12	Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin 2020 ·Journal of Controlled Release ·Jiří Trousil, Oto Pavliš, (unknown), Miša Škorič, V. Marešová, Ewa Pavlová, Kenneth D. Knudsen, (unknown), Matthew Zimmerman, Véronique Dartois, Jia‐You Fang, Martin Hrubý	29
13	Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development 2019 ·Nature Communications ·(unknown), Kathryn O’Brien, Divya Tiwari, Curtis A. Engelhart, Shaun B. Walters, (unknown), Hee‐Jeong Yang, (unknown), Dominique J. Wiener, Emmanuel K. Dayao, Matthew Zimmerman, Brendan Prideaux, Prashant Desai, Thierry Masquelin, Laura E. Via, Véronique Dartois, Helena I. Boshoff, Clifton E. Barry, Sabine Ehrt, Dirk Schnappinger	86
14	Investigation of (S)-(−)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase 2019 ·ACS Infectious Diseases ·Matthew R. Bockman, Curtis A. Engelhart, (unknown), (unknown), Neeraj K. Mishra, Matthew Zimmerman, Peter Larson, Nadine Álvarez, Sae Woong Park, Helena I. Boshoff, James Bean, Victor G. Young, David M. Ferguson, Véronique Dartois, Joseph T. Jarrett, Dirk Schnappinger, Courtney C. Aldrich	26
15	Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization 2019 ·PLoS Medicine ·Natasha Strydom, Sneha Gupta, (unknown), Laura E. Via, Hyeeun Bang, Myungsun Lee, Seok‐Yong Eum, Tae Sun Shim, Clifton E. Barry, Matthew Zimmerman, Véronique Dartois, Radojka M. Savić	134
16	Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation 2018 ·eLife ·(unknown), Liping Li, Matthew Zimmerman, (unknown), Yuxiang Chen, Melody Toosky, Michelle Gardner, Miaomiao Pan, Yangyang Li, (unknown), Junhao Zhu, Hong-Wei Su, Amanda J. Martinot, Eric J. Rubin, Véronique Dartois, Babak Javid	24
17	Targeting protein biotinylation enhances tuberculosis chemotherapy 2018 ·Science Translational Medicine ·Divya Tiwari, Sae Woong Park, (unknown), Surendra Dawadi, (unknown), Madhumitha Nandakumar, Matthew Zimmerman, (unknown), (unknown), Curtis A. Engelhart, Thomas R. Ioerger, James C. Sacchettini, Kyu Y. Rhee, Sabine Ehrt, Courtney C. Aldrich, Véronique Dartois, Dirk Schnappinger	24
18	Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery 2015 ·PLoS ONE ·Sean Ekins, Peter B. Madrid, Malabika Sarker, Shao-Gang Li, Nisha Mittal, Pradeep Kumar, Xin Wang, (unknown), Matthew Zimmerman, Carolyn Talcott, Pauline Bourbon, Mike Travers, Maneesh K. Yadav, Joel S. Freundlich	17
19	Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates 1995 ·Journal of Hepatology ·Rita Lin, (unknown), Matthew Zimmerman, Simone I. Strasser, Geoffrey C. Farrell	107
20	Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. 1989 ·Journal of Clinical Oncology ·Scott Wadler, Edward L. Schwartz, Marc Goldman, (unknown), Michael Rader, Matthew Zimmerman, Loretta M. Itri, V. Weinberg, P H Wiernik	271

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact